GLYCOTOPE BIOTECHNOLOGY
Glycotope Biotechnology is a contract manufacturer for active biopharmaceutical ingredients (bio APIs) such as proteins and antibodies using know-how in biotechnological recombinant protein production. They are located in Heidelberg, the hot spot of life sciences in Germany. Glycotope Biotechnology is operating GMP compliant as defined by current ICH guidelines and has been certified according ISO 9001. The facilities are also approved according to the corresponding German laws for Gene Technology (GenTG), Control of Epidemics (IfSG, BioStoffV) and Protection against Radiation (StrISchV). The manufacturing facilities are approved for the bulk API production of proteins for pharmaceutical purposes.
GLYCOTOPE BIOTECHNOLOGY
Industry:
Biotechnology
Founded:
2001-01-01
Address:
Heidelberg, Baden-Wurttemberg, Germany
Country:
Germany
Website Url:
http://www.glycotope.com
Total Employee:
51+
Status:
Active
Contact:
493094892630
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Wordpress Plugins Nginx Sitelinks Search Box
Founder
Newest Events participated
Participated in BIO-Europe 2017 | November 6–8 in Berlin, Germany
on 2017-11-06 as exhibitor
Official Site Inspections
http://www.glycotope.com Semrush global rank: 5.86 M Semrush visits lastest month: 1.41 K
- Host name: ssl01.e-pixler.network
- IP address: 116.202.183.166
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "Glycotope Biotechnology"
Tumor-Targeting Antibodies | Glycotope
Glycotope is an asset management and former biotechnology company focused on the management and commercialization of its own license agreements and related assets.See details»
Glycotope Biotechnology - Crunchbase Company Profile & Funding
Glycotope Biotechnology is a contract manufacturer for active biopharmaceutical ingredients (bio APIs) such as proteins and antibodies using know-how in biotechnological recombinant protein …See details»
Glycotope Company Profile 2024: Valuation, Investors ... - PitchBook
Glycotope General Information Description. Developer of a glycobiology technology designed to address tumor-specific glycol-epitope targets. The company's technology is focused on the …See details»
Glycotope Company Profile - Office Locations, Competitors ... - Craft
Apr 8, 2022 Glycotope Presents GlycoTarget Platform and New Data on Platform-Derived anti-LYPD3 Antibody at 2022 Society for Immunotherapy of Cancer (SITC) Meeting Nov 8, 2022 …See details»
Pentixapharm Acquires Target Discovery Business of Glycotope
Jul 3, 2024 It also includes Glycotope’s laboratories, cell banks, tumor target data base, and the equipment needed to exploit the discovery platform, along with a range of patents, licenses, …See details»
Glycotope Announces New Strategy to Maximize Potential of
Mar 24, 2022 Glycotope GmbH Henner Kollenberg CEO Phone: +49 30 9489 2600 E-Mail: [email protected] Media Contact: Chris Gardner, Chris Welsh Consilium Strategic …See details»
Glycotope to spin-out its Service Business to the newly formed …
Feb 1, 2022 Glycotope to spin-out its Service Business to the newly formed FyoniBio GmbH Berlin, Germany, February 1, 2022 - Glycotope GmbH, a biotechnology company developing …See details»
Glycotope Presents Glyco-Engineered Cell Lines at the …
Berlin, Germany, 17 April, 2023 – Glycotope GmbH, a biotechnology company utilizing a proprietary platform technology to developing antibodies against proteins carrying tumor-specific carbohydrate structures, today announces …See details»
Glycotope Presents Glyco-Engineered Cell Lines at the 2023
Glycotope Presents Glyco-Engineered Cell Lines at the 2023 ... - BioSpaceSee details»
Glycotope Presents Glyco-Engineered Cell Lines at the 2023
Berlin, Germany, 17 April, 2023 – Glycotope GmbH, a biotechnology company utilizing a proprietary platform technology to develop antibodies against proteins carrying tumor-specific …See details»
Glycotope Presents GlycoTarget Platform and New Data on …
Poster hall: 11 November 2022, 9:00am - 9:00pm EST Abstracts will be available on SITC’s website located at www.sitcancer.org at 8am EST on Nov. 7, 2022. Contact Information:. …See details»
Glycotope and Evotec enter licensing agreement to combine …
Dec 11, 2023 Glycotope and Evotec enter licensing agreement to combine Glycotope antibodies and Evotec’s immune cell engager platform Berlin, Germany, 11 December 2023 – Glycotope …See details»
Glycotope Presents GlycoTarget Platform and New Data on
Aug 11, 2022 Glycotope Presents GlycoTarget Platform and New Data on Platform-Derived anti-LYPD3 Antibody at 2022 Society for Immunotherapy of Cancer (SITC) Meeting. Berlin, …See details»
Daiichi Sankyo Enters Worldwide Licensing Agreement with …
Jul 30, 2018 Glycotope is a clinical-stage immuno-oncology company built on world-leading glyco-biology expertise. The company draws on its long experience in glyco-biology to create …See details»
Glycotope Presents New Data on Carbohydrate-Dependent …
Nov 15, 2021 Glycotope Poster Presentation at the 2021 Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting. Berlin, Germany, November 15, 2021 – Glycotope GmbH, a …See details»
4 Targeting of a cancer-associated LYPD3 glycoform for
Correspondence to [email protected]; Glycotope, Berlin, Germany GT-002 specifically binds to O-glycosylated LYPD3 (ELISA, flow cytometry) • Neuraminidase treatment …See details»
Glycotope Presents New Data on Antibodies and - GlobeNewswire
Apr 8, 2022 Glycotope GmbH Dr. Patrik Kehler CSO Phone: +49 30 9489 2600 E-Mail: [email protected]: Media Contact: Chris Gardner, Chris Welsh Consilium Strategic …See details»
Glycotope’s Phase Ib solid tumour trial sees five-point drop
Jun 17, 2021 Glycotope’s tomuzotuximab in epidermal growth factor receptor (EGFR) expressing solid tumours saw its Phase Transition Success Rate (PTSR) drop five points to …See details»
Antibodies against GlycoTargets as novel platform approach to …
[email protected]; Glycotope, Berlin, Germany Tumor-Associated O-Glycans GlycoTargets Case Study: Antibody Discovery against GlycoTarget Y GlycoTargets for …See details»
Protein (O-glyc) Carbohydrate-dependent protein binding
[email protected]; Glycotope, Berlin, Germany Antibody Discovery: GlycoTarget X GlycoTargets Antibody Discovery: GlycoTarget Y Strictly O-glycosylation …See details»